pyrroles has been researched along with 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1h-indol-5-yl)-7h-pyrrolo(2,3-d)pyrimidin-4-amine in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atkins, C; Axten, JM; Feng, Y; Gampe, RT; Goetz, A; Grant, SW; Hassell, AM; Heerding, DA; Hong, X; Kahler, KM; Kumar, R; Li, WH; Liu, Q; Medina, JR; Mencken, T; Minthorn, E; Rabindran, S; Romeril, SP; Shewchuk, LM; Shu, A; Sigethy, SD; Stanley, T; Taylor, JD; Tomberlin, GH | 1 |
1 other study(ies) available for pyrroles and 7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1h-indol-5-yl)-7h-pyrrolo(2,3-d)pyrimidin-4-amine
| Article | Year |
|---|---|
Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK).
Topics: Adenine; Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Crystallography, X-Ray; Dogs; Drug Screening Assays, Antitumor; eIF-2 Kinase; Female; Humans; Indoles; Male; Mice; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Phosphorylation; Protein Conformation; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Transplantation, Heterologous | 2012 |